Stocks and Investing
Stocks and Investing
Wed, December 7, 2022
[ 12:00 AM ] - WOPRAI
Tue, December 6, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Terence Flynn Maintained (UTHR) at Buy with Increased Target to $330 on, Dec 6th, 2022
Terence Flynn of Morgan Stanley, Maintained "United Therapeutics Corporation" (UTHR) at Buy with Increased Target from $322 to $330 on, Dec 6th, 2022.
Terence has made no other calls on UTHR in the last 4 months.
There are 4 other peers that have a rating on UTHR. Out of the 4 peers that are also analyzing UTHR, 0 agree with Terence's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Terence
- Chris Shibutani of "Goldman Sachs" Initiated at Strong Sell and Held Target at $230 on, Monday, December 5th, 2022
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $375 on, Thursday, November 3rd, 2022
- Jessica Fye of "JP Morgan" Maintained at Buy with Increased Target to $265 on, Thursday, November 3rd, 2022
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $300 on, Thursday, November 3rd, 2022
Contributing Sources